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A B S T R A C T
We investigated the effects of the neuropeptide met-enkephalin on histamine-induced bronhoconstriction in an ex-
perimental model of asthma. Classic Konzett and Rössler’s method of whole body plethysmography modified by Gju-
ri{1, was applied in the study. This method represents a standard experimental model of bronchoconstriction, suitable
for the evaluation of peptide effects on the histamine-induced bronchoconstriction. The results of the measurements im-
plicate a dose-related modulatory effect of met-enkephalin on the bronchoconstrictor action of histamine. Met-enke-
phalin doses of 1 mg/kg and 10 mg/kg, respectively, caused statistically significant reduction of the histamine-induced
bronchoconstriction. Estimated ED50 dose was 0.235 mg/kg. Further studies are needed to define practical and thera-
peutical use of the presented observations in respiratory pharmacology.
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Introduction
We evaluated the effects of the neuropeptide met-enke-
phalin on experimentally induced bronchoconstriction
in guinea pigs. Classic Konzett and Rössler’s method of
whole body plethysmography modified by Gjuri{1,2 was
applied in this study, since it represents a standard ex-
perimental model of bronchoconstriction, suitable for
the evaluation of peptide effects on the histamine in-
duced bronchoconstriction.
Met-enkephalin is an endogenous opioid pentapep-
tide with the amino acid sequence Tyr-Gly-Gly-Phe-Met
(molecular weight, MW=573.7). Molecular precursors of
met-enkephalin are pro-opiomelanocortin (POMC) and
preproenkephalin hormones3. Preproenkephalin molecule
contains six copies of met-enkephalin and pro-opiome-
lanocortin one copy3. Met-enkephalin binds preferen-
tially to delta opioid receptors3,4. Recent investigations
showed that zeta opioid receptors mediate its effects on
cellular and tissue growth and development5.
Met-enkephalin was investigated because of its pres-
ence in the respiratory tract6,7 and several previous re-
ports showing that it blocks »in vivo« effects of hista-
mine in the models of anaphylactic shock, hypersensi-
tivity reactions and autoimmune diseases4,8,9. Recent
pre-clinical and clinical studies of met-enkephalin indi-
cated that it could be a promising new drug for different
autoimmune and chronic inflammatory diseases4,5,8–15.
Materials and Methods
Animals
Experimental animals were male and female (1:1)
Hartley guinea pigs bred at the Department of Pharma-
cology, Zagreb University School of Medicine, weighing
500–700 g. The animals were kept in a room with con-
stant temperature (22±1°C) and dark-light cycle (12h/
12h). They were fed by standard laboratory food and
given water ad libitum. During the experiment animals
were anesthetized with 1.5 g/kg body weight of urethan
(25% solution). Two thirds were administered intra-
peritonealy and the rest subcutaneously. When needed,
additional anesthesia was given intravenously. This
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type of anesthesia minimally suppresses respiratory
reflexes1. Guinea pigs are suitable for plethysmogra-
phyic evaluation because of rich smooth muscle network
around the bronchioles that is highly sensitive to his-
tamine16. The protocol of the investigation complied
with the European Community guidelines for the use of
experimental animals, and was approved by the institu-
tional ethics committee.
Method
Whole body plethysmography with continuous spi-
rogram registration allows monitoring of any change in
the respiratory rate, type of respiration or amplitude of
respirations. Konzett and Rössler’s method of whole
body plethysmography, modified by Gjuri{, was applied
in this study1,2.
Bronchoconstriciton was induced by intravenous his-
tamine (10 g/kg). Each animal was it’s own control, i.e.,
the histamine responses without pretreatment were
compared to histamine responses following pretreat-
ment with the tested substances, measured as changes
in the amplitude of respirations. The protective effect of
met-enkephalin was defined as the percentage of hista-
mine blockade (the reduction of histamine-induced
bronchoconstriction). Met-enkephalin (LUPEX®, Biofac-
tor, Germany) was administered in three doses (0.1
mg/kg, 1 mg/kg, 10 mg/kg). Investigated met-enkepha-
lin doses, presented in Table 1, were given intrave-
nously, 90 seconds prior to histamine. Plethysmography
was performed continuously.
Data analysis
Statistical analysis and data plotting was performed
with GraphPad Prism Software (version 4.0). The differ-
ences between effects of observed met-enkephalin doses,
on the histamine induced bronchoconstriction, were
tested by means of Kruskall-Wallis test, and Dunn’s
multiple comparison test.
Results
The lowest doses of 0.1 mg/kg met-enkephalin caus-
ed no statistically significant change in the histamine-
-induced bronchoconstriction (Table 2). Met-enkephalin
doses of 1 mg/kg and 10 mg/kg, respectively, caused sta-
tistically significant reduction of the histamine induced
bronchoconstriction (Table 2 and Figure 1). The highest
dose of 10 mg/kg met-enkephalin had the best pharma-
cological effect (Table 2, Figures 1–2).
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TABLE 1




(substance and dose applied pro animal)
A
N = 6
histamine 10 g/kg (control for goup A)




histamine 10 g/kg (control for goup B)




histamine 10 g/kg (control for goup C)
met-enkephalin 10 mg/kg, histamine 10 g/kg,
90 seconds later

















Fig. 1. Blockade of histamine bronchoconstriction by means
of different met-enkephalin doses.
TABLE 2





0.1 mg/kg (A) 1 mg/kg (B) 10 mg/kg (C)
1 6.7 42.9 66.7
2 0.0 0.0 35.7
3 0.0 25.0 0.0
4 5.0 50.0 62.5
5 0.0 40.0 50.0
6 21.4 46.2 44.5
Kruskal-Wallis test: 6.97, p < 0.05, Dunn’s multiple comparison
test: A vs. B: rank sum = –5.75, p > 0.05, A vs. C: rank sum =
–7.75, p < 0.05, B vs. C: rank sum = –2.00, p > 0.05
















Fig. 2. Dose-response curve of the met-enkephalin induced
reduction of histamine bronchoconstriction.
The results of the measurements implicate a dose-re-
lated modulatory effect of met-enkephalin on the bron-
choconstrictor action of histamine in the experimental
model of bronchoconstriction, as presented in Figure 2.
Estimated ED50 dose17 was 0.235 mg/kg (R2=0.617).
Discussion
Met-enkephalin is a multifunctional neuropeptide
that exerts gut cytoprotection, in addition to a number
of other antiinflammtory and immunomodulating ef-
fects on different organs and tissues4,5,8–14. Consequ-
ently, it was recently proposed to be classified as a
cytokine4.
The beneficial effects of the met-enkephalin were re-
ported for several disease models including arthritis,
encephalomyelitis, graft-versus host reaction, ischae-
mia and inflammatory bowel disease4,5,8–14. The pen-
tapeptide also induces analgesia, and antioxidant ac-
tion4,13,14,18. According to the present knowledge the ad-
ministration of met-enkephalin enables pharmacologic
effects of both steroidal and non-steroidal antiinflam-
matory drugs, without the majority of their side-ef-
fects8,,9,13,14.
Despite of the extensive studies, including pre-clini-
cal pharmacology and several clinical trials of different
autoimmune diseases, tumors, AIDS and infertili-
ty4,5,9,10,13,14,19,20, met-enkephalin was not (to our knowl-
edge) investigated with respect to asthma therapy. Met-
-enkephalin and its metabolic activity were detected in
the rat and guinea pig respiratory tract6,7,21. However,
no changes in the plasma met-enkephalin were found in
acute asthma bronchoconstriction produced by exerci-
se22. The inhibition of non-adrenergic non-cholinergic
bronchoconstriction in guinea pig airways was reported
to be via mu-opioid receptors23 that bind met-enke-
phalin with low affinity4. This study showed that met-
-enkephalin significantly reduces histamine induced
bronchoconstriction in guinea pigs regardless of the fact
that it is a peptide selective for delta and zeta opioid
receptors4,5. Local immunoregulatory role of preproen-
kephalin and met-enkephalin may be also of interest for
the immunotherapy of asthma24.
The results of our study, conducted on the classic
model of experimental bronchoconstriction, indicate that
further investigations are justified. The localization of
the peptide within the respiratory tract2,6,7, seems to be
in line with our observation that met-enkephalin doses
of 1 mg/kg and 10 mg/kg, respectively, cause statisti-
cally significant reduction of the histamine induced
bronchoconstriction. Estimated ED50 dose of 0.235 mg/kg
is also in the range of pharmacologically active human
met-enkephalin doses, applied subcutaneously, in dif-
ferent autoimmune diseases and tumors4,9,10,13,14. Fur-
ther studies are needed to define possible therapeutic
targets, doses and modes of met-enkephalin administra-
tion in respiratory pharmacology.
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U^INCI MET-ENCEFALINA U EKSPERIMENTALNOM MODELU BRONHOKONSTRIKCIJE
S A @ E T A K
U radu su ispitani u~inci neuropeptida met-encefalina (LUPEX) na bronhokonstrikciju izazvanu histaminom u
eksperimentalnom modelu astme. Uporabljena je klasi~na metoda pletizmografije cijelog tijela po Konzettu i Rös-
sleru, modificirana po Gjuri{u. Metoda predstavlja standardni eksperimentalni model bronhokonstrikcije, pogodan
za procjenu efekta peptida na bronhokonstrikciju izazvanu histaminom. Mjerenja su ukazala da je modulatorni u~i-
nak met-encefalina na ovisan o dozi. Doze met-encefalina od 1 mg/kg i 10 mg/kg izazvale su statisti~ki zna~ajnu
redukciju histaminom inducirane bronhokonstrikcije. Procjenjena ED50 doza bila je 0.235 mg/kg. Dodatne studije
potrebne su kako bi se definirali mogu}i terapijski u~inci met-enkefalina u respiratornoj farmakologiji.
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